This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
A series of software upgrades is likely to provide Accuray (ARAY) a competitive edge in the radiation-oncology space.
Here's Why You Should Buy Wright Medical (WMGI) Stock Now
by Zacks Equity Research
A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Here's Why You Should Hold Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
by Zacks Equity Research
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.
Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid
by Zacks Equity Research
Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.
AmerisourceBergen (ABC) Beats on Q1 Earnings, Trims EPS View
by Zacks Equity Research
AmerisourceBergen (ABC) registers solid growth at the Pharmaceutical Distribution segment and the World Courier business in first-quarter fiscal 2019.
Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.
SurModics (SRDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 1300.00% and 17.68%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
by Zacks Equity Research
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics, Inc. (SRDX) has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why You Should Invest in Veeva Systems (VEEV) Now
by Zacks Equity Research
Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.
Hill-Rom-Microsoft Tie-Up to Widen Digital Solutions Suite
by Zacks Equity Research
Hill-Rom (HRC) progresses with efforts to gain traction in the digital health space.
Integra (IART) Rises 5% on Robust Preliminary Q4 Results
by Zacks Equity Research
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
Boston Scientific Gains on Impressive Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
ResMed Announces Complete Mobi Launch in US Markets for COPD
by Zacks Equity Research
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
by Zacks Equity Research
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Hologic Stock Rides on Impressive Preliminary Q1 Result
by Zacks Equity Research
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
ResMed Closes Propeller Health Buyout, Boosts COPD Suite
by Zacks Equity Research
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.